Biotrial

Rennes 16 trials 5 recruiting

16 Registered trials

5 Currently recruiting

Organisation

Biotrial

Location

Rennes, France

Identifier

ORG-100006463

Address

7 Rue Jean Louis Bertrand, 35000, France

Departments

Unité Clinique

Clinical trials at this site (16)

Search interface

A phase 1, randomized, double-blind, placebo-controlled study investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics… Not authorised

2024-512106-26-00 Cognitive impairment 1
A randomized, open-label, two-period, two-sequence crossover trial to investigate the effect of food on the pharmacokinetics of Silexan 80 m… Pending

2024-514373-22-00 Healthy volunteers 3
First in human, Phase 1a/1b Study of KM-023 in healthy volunteers and Olmsted syndrome patients Recruiting

2025-521446-20-00 Olmsted syndrome 1 2025-06-27
A Safety Study to Test a New Medicine (ANT3310) Alone and When Taken with an Antibiotic (Meropenem) in Healthy Adult Participants. Recruiting

2026-526411-11-00 Not applicable for phase I study 3 2026-06-15
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ST‑905‑AG1 in Healthy Volunteers Recruiting

2026-525700-10-00 Schizophrenia 1 2026-06-08
A trial to test the safety and tolerability of Lu AH70212 and Lu AH69593 in healthy adults. Recruiting

2025-522652-58-01 Narcolepsy 1 2026-02-19
A trial to investigate the safety and pharmacokinetics of GRT6019 in healthy male participants. Recruiting

2025-523587-20-00 Not applicable for phase I study 3 2026-01-05
A Phase 1/2a Study of Safety, Pharmacokinetics and Neutralizing Activity of SPK002 as pre-exposure prophylaxis of COVID-19 in healthy volunt… Ended

2023-505279-62-00 Immunocompromised individuals (phase 2a) 7 2023-07-10
A Randomised, Open-Label, Single-Centre, Study to Evaluate the Bioequivalence of Lanifibranor Ended

2025-524385-18-00 Non-alcoholic steatohepatitis 2 2026-02-11
Phase I, first-in-man, randomised, placebo-controlled, single dose escalation study to investigate the effects of LPH-5 on safety, tolerabil… Ended

2024-512330-15-00 Depression 1 2025-08-05
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Adaptive Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Phar… Ended

2025-521914-25-00 Schizophrenia 3 2025-07-31
A multicentric, open-label, non-randomized study to evaluate the pharmacokinetic, safety and tolerability of ITF2357 given as an oral single… Ended

2024-513577-43-00 Participants with normal hepatic function 3 2025-05-16
A Phase I, randomized, controlled, Latin-square, open-label study, to evaluate the effect of ADV7103 on gastric pH under fed and fasting con… Ended

2024-518764-13-00 distal renal tubular acidosis (dRTA) 3 2025-02-25
A phase 1, randomized, double-blind, placebo-controlled study investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics… Ended

2024-512106-26-02 Cognitive impairment 1 2024-11-19
A phase I randomized, investigator and participant-blind, adaptive, multiple-ascending dose, parallel and four-way crossover, placebo-contro… Ended

2023-504794-20-00 Healthy participants (part 1 and part 2) 3 2023-10-26
A randomised, open-label, reference-replicated crossover trial to investigate the bioequivalence of two formulations of Silexan 80 mg in hea… Ended

2023-503647-34-00 Healthy volunteers 2 2023-08-31